Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jakavi

Bristol Myers Squibb logo

Opdivo boosts survival in head and neck cancer by 30%

Pivotal trial of BMS’ PD-1 inhibitor shows "significant benefit" in overall survival

- PMLiVE

Novartis kicks back against US corruption charges

Investigation ‘explodes’ with US government information request on 79,000 physicians events

- PMLiVE

IQWiG unimpressed with Cosentyx in two new indications

Concludes Novartis drug has no added benefit in ankylosing spondylitis or psoriatic arthritis

Novartis building

NICE backs Novartis’ Entresto for heart failure

But approves narrower indication than has been authorised by Scotland's SMC

- PMLiVE

NICE promises UK to lead Europe for cancer drug approvals

But industry says running the new CDF will present NICE with a ‘hugely challenging’ task

- PMLiVE

Focus on multiple myeloma treatment: Witnessing a transformation

Consultant David Cooney of Blue Latitude Health will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.

Blue Latitude Health

Novartis and Microsoft test Kinect MS tool

The partners have a proof-of-concept for a system that could measure the condition's symptoms

Bristol Myers Squibb logo

Opdivo backed for two new uses by CHMP

Recommended for additional European approvals in kidney cancer and NSCLC

- PMLiVE

New UK Cancer Drugs Fund takes shape

NICE to manage access to cancer treatments from 1 July

Novartis building

Novartis claims FDA breakthrough status for leukaemia treatment

Designation could speed up development and access for Novartis’ PKC412

Eli Lilly HQ

Lilly wins European approval for lung cancer drug Portrazza

First biologic licenced in EU as a first-line treatment for adults with NSCLC

- PMLiVE

Astellas: Ten years young

Ken Jones and Sef Kurstjens on the company's progress and plans

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links